Aims: Therapeutic inertia, defined as the failure to initiate or intensify therapy in a timely manner according to evidence-based clinical guidelines, is a key reason for uncontrolled hyperglycaemia in patients with type 2 diabetes. The aims of this systematic review were to identify how therapeutic inertia in the management of hyperglycaemia was measured and to assess its extent over the past decade. Results: The final selection for the review included 53 articles. Measurements used to assess therapeutic inertia varied across studies, making comparisons difficult. Data from low-to middle-income countries were scarce. In most studies, the median time to treatment intensification after a glycated haemoglobin (HbA1c) measurement above target was more than 1 year (range 0.3 to >7.2 years). Therapeutic inertia increased as the number of antidiabetic drugs rose and decreased with increasing HbA1c levels. Data were mainly available from Western countries. Diversity of inertia measures precluded meta-analysis.
| INTRODUCTION
The importance of glycaemic control in patients with type 2 diabetes to reduce the risk of microvascular and macrovascular complications is well established [1] [2] [3] [4] [5] and widely recognized by current clinical guidelines. [6] [7] [8] [9] [10] For example, the joint position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) advocates a change of therapy if glycated haemoglobin (HbA1c) targets are not achieved after 3 months. 6 Despite the introduction of many glucose-lowering therapies that have proved to be efficacious in clinical trials, glycaemic control remains suboptimal in many patients globally. For example, in
European countries with broad access to glucose-lowering therapies, the GUIDANCE (N = 7597) and PANORAMA (N = 5817) studies showed that only 53.6% and 62.6% of patients, respectively,
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achieved the recommended HbA1c target of ≤7% (53 mmol/ mol). 11, 12 Several studies have identified 2 main reasons for suboptimal glycaemic control in clinical practice: (1) patient non-adherence to prescribed treatment and (2) clinical or therapeutic inertia, defined as the failure to initiate or intensify therapy in a timely manner according to evidence-based clinical guidelines in individuals who are likely to benefit from such intensification. 13, 14 The reasons for clinical or therapeutic inertia are multiple and complex, and include patient-, physician-and system-level barriers. 15 The primary objective of this systematic review was to identify studies assessing the extent of therapeutic inertia in the treatment of hyperglycaemia in different populations of patients with type 2 diabetes. The secondary objective was to provide an overview of how therapeutic inertia was defined and assessed in different studies.
Assessing the extent of therapeutic inertia is key to implementing interventions to reduce its occurrence, which will contribute to improving glycaemic control and ultimately patient outcomes.
| MATERIALS AND METHODS
This systematic review was registered with the International Prospective Register of Systematic Reviews (PROSPERO) on April 13, 2016 (registration number CRD42016036483) and followed Preferred
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Therefore, related terms were used instead (eg, "clinical competence,"
| Data sources and searches
"health care delivery" and "guideline adherence"). Detailed search strings used for both MEDLINE and Embase, and the corresponding numbers of identified publications are shown in Tables S1 and S2, respectively.
| Study selection
Broad inclusion criteria were used to minimize the risk of excluding relevant studies. All publications involving studies of patients with type 2 diabetes that reported a quantitative measure of therapeutic inertia were included. Conversely, articles covering studies with insufficient data (eg, those without a description of the intensification step and those not reporting the glycaemic level threshold used to determine whether treatment intensification was required) were excluded.
No language restrictions were imposed, to increase the likelihood of finding data from as many countries as possible. Congress abstracts were excluded from this systematic review because they do not provide sufficient data for effective analysis. Non-original research articles (eg, editorials, letters, comments, guidelines and reviews) were also excluded. No other quality criteria were used to exclude studies from the systematic review.
Two researchers, S. Pi. and Andrew Mayhook (Oxford PharmaGenesis, Oxford, UK), screened all titles and abstracts independently, in accordance with the inclusion and exclusion criteria described above. Full texts were retrieved for publications that met the inclusion criteria and for those that could not be adequately assessed for inclusion with the information provided in the abstract. The 2 researchers independently assessed the full texts for inclusion and discussed their decisions before reaching a consensus on the final list of articles to be included in the review.
| Data extraction
Data were extracted by a single researcher (S. Pi.). A standardized form was used to collect the following items when available: authors, year of publication, location, study design, period, sample size, patient and physician characteristics, definition of treatment intensification, glucoselowering agents used before and after treatment intensification, and measure(s) of therapeutic inertia (including the HbA1c threshold used to identify patients who required treatment intensification).
| RESULTS
Out of 7698 combined search results, 53 articles were identified that reported at least 1 measure of therapeutic inertia in the management of hyperglycaemia in individuals with type 2 diabetes. 16, The main reasons for exclusion of publications other than duplicates and those covering irrelevant topics were that they reported non-original research (eg, editorials, letters, comments and guidelines) or they were congress abstracts ( Figure 1 ). In addition, articles reporting the time to treatment intensification without reporting HbA1c results (eg, the time from type 2 diagnosis to insulin therapy initiation) were excluded.
| Study characteristics
Study characteristics are summarized in Table S3 . The majority of studies were conducted in North America (29 studies) and Europe (20 studies). Three studies were carried out in Asia, 35, 47, 53 and a single study was conducted in Israel. 62 Articles mainly reported data from cohort studies, using data from medical records or chart reviews, Patients were managed by primary care providers in 21 studies, 19, 21, 25, 34, [37] [38] [39] 41, 44, 45, 48, 50, 53, 54, [59] [60] [61] [63] [64] [65] 67 by both primary care providers and secondary care specialists in 6 studies, 23, 30, 35, 47, 58, 68 and by secondary care specialists alone in 1 study. 69 The healthcare providers responsible for patient care were not described in 25 studies. 16,18,20,22,24,26- 
| Measures of therapeutic inertia
There is no accepted measure to describe clinical or therapeutic inertia. For the purpose of this systematic review, studies were classified into 4 categories based on the measurement(s) used to quantify clinical/therapeutic inertia: (1) the mean or median length of time between at least one HbA1c measurement above a certain threshold and treatment intensification 18, 23, 28, 38, 43, 50, 54, 56, 62, 66 ; (2) 
| Time to treatment intensification
Results from the 10 publications that reported the median time to treatment intensification are shown in Table S3 and Figure 2 . For patients who received a single OAD, 23, 28, 29, 50, 62, 66 the median time to treatment intensification with any drug (ie, by addition of 1 OAD or insulin/other injectable drug) was 0.3 to 2.7 years after at least 1 HbA1c measurement above target. The time to treatment intensification was generally longer in studies that included patients treated with more than one OAD and ranged from 1.3 to 4.9 years. 18, 43, 54, 56 In most of these studies, less than 50% of the patients received treatment intensification before the end of the follow-up period. The study by Rubino et al. specifically reported treatment intensification with insulin in patients using 2 or more OADs. 54 The time to treatment intensification estimated by Kaplan-Meier survival analysis was 4.9 and 4.2 years for patients with HbA1c levels of ≥8.0% and ≥9.0%, respectively. A single study assessed therapeutic inertia in patients using basal insulin. 38 The time to treatment intensification (addition of bolus insulin, premix insulin or a GLP-1 receptor agonist) was esti- Modified Healthcare Effectiveness Data and Information Set (HEDIS) target of HbA1c <7.0% for patients aged <65 years without evidence of significant morbidities and HbA1c <8.0% for all other patients (set by the National Committee for Quality Assurance Healthcare in 2013).
** Median time to treatment intensification calculated only for patients who received treatment intensification during the study period. † † Fewer than 50% of patients had received treatment intensification by the end of the study period.
‡ ‡ Estimated by Kaplan-Meier analysis.
GLP-1 RA, glucagon-like peptide-1 receptor agonist; HbA1c, glycated haemoglobin; OAD, oral antidiabetic drug; TI, treatment intensification
| Proportion of patients who received treatment intensification
A total of 34 studies reported the proportions of patients who received treatment intensification within a given a period of time (Table S3) . 18, 19, 21, 22, 24, 25, [27] [28] [29] 31, 32, 35, 37, 40, 42, 43, 46, 47, [50] [51] [52] [53] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] Results from studies that included a single treatment intensification step (eg, a specific number of OADs at baseline) and those combining several baseline treatments (eg, baseline treatment described as other than insulin) are summarized in Figures 3 and 4 , respectively.
In most of these studies, less than 50% of patients received treatment intensification for follow-up periods of less than 12 months. Exceptions were observed for patients managed with diet and exercise only at baseline 40 and for patients with HbA1c levels ≥9.0%. 47, 53 Four other studies found treatment intensification in more than 50% of patients within 6 months or less of having an HbA1c level above target. 35, 55, 57, 63 In 3 of these studies, patients were managed by physicians taking part in a pay-per-performance programme, 35 or they were members of a large, integrated managed care consortium (Kaiser Permanente Northern California). 55, 57 The fourth study was a post hoc analysis of a randomized controlled trial concerning the implementation of locally adapted guidelines. 63 Unsurprisingly, for studies that considered several follow-up periods, the proportion of patients who received treatment intensification rose with increasing lengths of follow-up. Nevertheless, even after periods longer than 12 months following an HbA1c measurement above target, the proportion of patients who had received treatment intensification was only 37% to 79%. 18, 19, 28, 51, 65 In 4 studies in which different HbA1c thresholds were analysed, the 40 Rajpathak, 2014 51 Tunceli, 2015 62 Watson, 2016 65 Paul, 2015 50 Ajmera, 2015 18 Yu, 2016 66 Balkau, 2012 19 Grant, 2007 31 Balkau, 2012 19 Balkau, 2012 19 First author, year In the single study that reported proportions of patients receiving treatment intensification within 6 months for different treatment regimens, 43 proportions were lower for insulin (5% to 6%) and GLP-1 receptor agonists (2% to 3%) than for addition of an OAD (20% to 21%).
| Glycaemic burden
Five publications reported glycaemic burden (ie, the length of time with HbA1c above target during a given period). 16, 34, 36, 39, 69 Results of these studies are summarized in Figure 5 and 36, 69 In the study by Halimi et al. 34 patients with poor glycaemic control were identified during a routine visit, and the length of time their HbA1c level had been above target was calculated using medical records.
In the study by Brown et al. 16 the mean glycaemic burden ranged from 0.7 to 4.9 years, depending on therapy and HbA1c threshold. Glycaemic burden increased with the rising number of OADs used and was lower for patients with HbA1c levels >8.0% than for those with for patients with HbA1c levels ≥7.0%, 7.5% and 8.0%, and decreased with the increasing number of OADs; these proportions were lower when treatment was intensified with insulin (7% to 22%) than when it was intensified with an OAD (30% to 67%). Halimi et al. identified patients who received OADs and whose HbA1c was inadequately controlled (2 consecutive HbA1c measurements ≥6.5%, ≥7.0% and ≥8.0%
for patients treated with 1, 2 and 3 OADs, respectively). 34 Although the HbA1c level had been over target for 0.9 to 1.2 years in these patients, few individuals (0% to 7%) received treatment intensification during the inclusion visit. In the study by Zografou et al. 69 glycaemic burden was assessed from diagnosis to insulin treatment initiation; the median time above target was 0.8 to 4.2 years and decreased with increasing HbA1c values. In the study by Hugie et al., 36 glycaemic burden (HbA1c >8.0%) before insulin treatment initiation was 0.4 to 1.3 years and rose with the increasing number of OADs.
| Other measures of therapeutic inertia
In addition to the studies above, 12 others determined the proportions of patients who received treatment intensification without specifying a time frame 30, 33, 34, 44 or measured therapeutic inertia by assessing the proportion of clinical encounters for which treatment intensification was recommended by guidelines and did not occur (Table S3) . 20, 26, 41, 45, 48, 49, 67, 68 In 4 of these studies, treatment intensification was assessed by questionnaires completed by physicians 41, 45, 49 or patients. 48 The different and insufficiently described methodologies precluded any comparisons among these studies. In the study by Ziemer et al., 68 treatment intensification rates increased with rising plasma glucose levels and were higher in specialist care than in primary care settings. Similarly, in the studies by Parchman et al. 48 and Parnes et al., 49 Other methodological aspects of some of the studies should be carefully considered when interpreting the results and the degree to which they represent therapeutic inertia. Several studies quantified therapeutic inertia by calculating the number of visits during which treatment intensification was indicated by guidelines but did not occur. 41, 45, 68 This approach may not provide a representative picture of therapeutic inertia. At the level of a visit, competing demands may prevent treatment intensification, particularly in primary care. As visits are time-constrained, physicians and patients may prioritize more pressing issues (eg, symptomatic comorbidity or counselling for smoking-cessation) and thus delay treatment intensification to another visit. 48 Competing demands were one of the main reasons for inaction cited by healthcare providers in the study by Parnes et al. 49 In this context, there is an opportunity for pharmacists to play 
